This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Aaron M. Shapiro, BSc; Carolyn S. Jack, BSc; Yves Lapierre, MD; Nathalie Arbour, PhD; Amit Bar-Or, MD; Jack P. Antel, MD

Arch Neurol. 2006;63:1296-1299.

Background  A proportion of patients with multiple sclerosis (MS) receiving systemic interferon beta therapy will develop serum neutralizing antibodies (NAbs) that can reduce the activity of the drug. Interferon- (IFN-) is produced by glial cells within the central nervous system. Although systemic interferon beta does not access the central nervous system, titers of serum NAbs may be sufficient that some will access the central nervous system.

Objective  To address whether serum samples that contain high titers of NAbs could inhibit glial cell production of chemokines and cytokines that are regulated by endogenous IFN-.

Design  We used an in vitro assay involving toll-like receptor 3 ligand (polyinosinic-polycytidylic acid) signaling to assess the effect of serum samples containing high titers of NAbs (1800-20 000 U) on production of the chemokine CXCL10 and the cytokine interleukin 6 by human astrocytes.

Results  Serum samples positive for NAbs significantly inhibited polyinosinic-polycytidylic acid–induced CXCL10 and IL-6 production by astrocytes.

Conclusion  High-titer NAbs to interferon beta may block endogenous IFN- function and alter the chemokine/cytokine microenvironment within the central nervous system, thereby modulating the profile and course of the local inflammatory response.

Author Affiliations: Neuroimmunology Unit and Multiple Sclerosis Clinic, Montreal Neurological Institute (Mr Shapiro, Ms Jack, and Drs Lapierre, Arbour, Bar-Or, and Antel), and Centre Hospitalier de Universitaire de Montréal Research Center (Dr Arbour), Montreal, Quebec.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes
Reder
Mult Scler 2007;13:53-62.
ABSTRACT